Biotechnology · Burlington, Massachusetts, United States
$4.63
+0.00% (+$0.00)2026-07-09
Smart-Money SignalNeutral · 52/100— Insider open-market flow is flat over 90 days
Net Income-$125.4M
EPS$-2.86
Market Cap$203.0M
Price Performance
Historical data including institutional events
Company Profile
R
Remy Luthringer
CEO & Executive Director
Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases.
Its lead product candidate is roluperidone, which is in Phase 3 confirmatory trial for the treatment of negative symptoms in patients with schizophrenia.
Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts.
